BIIB

Biogen
D

BIIB

Arincen57/100B

Biogen return on equity (ROE)

Biogen's return on equity is -0.37%: net income of -69.50M USD over the last twelve months on shareholders' equity of 18.92B USD.

Today
-0.37%
Average, 5 years
10.99%
Low, 5 years
-0.37%
High, 5 years
22.69%

ROE (return on equity) = net income (last 12 months) ÷ shareholders' equity = -69.50M ÷ 18.92B = -0.37%

ROE (return on equity)
Net income
Shareholders' equity

Each quarter's net income over its last four quarters, over the shareholders' equity at the quarter end.

What drives Biogen's return on equity?

Net margin
13.1%
profit on each dollar of sales
Asset turnover
0.34×
sales on each dollar of assets
Equity multiplier
1.61×
assets on each dollar of equity
Return on equity
7.1%
FY2025
  • FY202513.1% × 0.34 × 1.61 = 7.1%
  • FY202416.9% × 0.34 × 1.68 = 9.8%
  • FY202311.8% × 0.37 × 1.81 = 7.8%
  • FY202229.9% × 0.41 × 1.83 = 22.7%
  • FY202114.2% × 0.46 × 2.19 = 14.3%

The DuPont breakdown, on each year-end's assets and equity, as the return on equity elsewhere on this page. A high equity multiplier means a small equity base: debt, or buybacks that return the equity to shareholders, lift the return on what is left.

ROE (return on equity) by year and by quarter

Fiscal yearPeriod endingROE (return on equity)Net incomeShareholders' equity
Today-0.37%-69.50M18.92B
FY202531 Dec 20257.08%1.29B18.26B
FY202431 Dec 20249.76%1.63B16.72B
FY202331 Dec 20237.85%1.16B14.80B
FY202231 Dec 202222.10%2.96B13.40B
FY202131 Dec 202115.86%1.73B10.90B
FY202031 Dec 202037.95%4.06B10.70B
FY201931 Dec 201944.13%5.89B13.34B
FY201831 Dec 201834.31%4.47B13.04B
FY201731 Dec 201721.17%2.67B12.61B
FY201631 Dec 201630.44%3.70B12.14B
FY201531 Dec 201538.34%3.59B9.37B
FY201431 Dec 201427.20%2.94B10.81B
FY201331 Dec 201321.60%1.86B8.62B
FY201231 Dec 201219.82%1.38B6.96B
FY201131 Dec 201119.71%1.27B6.43B
FY201031 Dec 201016.65%898.57M5.40B
FY200931 Dec 200915.70%977.06M6.22B
FY200831 Dec 200813.49%783.17M5.81B
FY200731 Dec 200711.53%638.17M5.53B
FY200631 Dec 20063.04%217.51M7.15B
FY200531 Dec 20052.33%160.71M6.91B
FY200431 Dec 20040.37%25.09M6.83B
FY200331 Dec 20030.00%0.007.05B
FY200231 Dec 200212.48%199.15M1.60B
FY200131 Dec 200120.22%272.68M1.35B
FY200031 Dec 200030.15%333.58M1.11B
FY199931 Dec 199922.51%220.45M979.53M
FY199831 Dec 199819.30%138.70M718.61M
FY199731 Dec 199716.63%89.17M536.29M
FY199631 Dec 19968.37%40.53M484.37M
FY199531 Dec 19951.48%5.66M382.98M
FY199431 Dec 1994-1.48%-4.90M329.93M
FY199331 Dec 19939.96%32.40M325.20M
FY199231 Dec 199213.44%38.30M285.00M
FY199131 Dec 19913.01%7.20M239.00M
FY199031 Dec 19905.28%7.70M145.70M
FY198931 Dec 19892.30%3.20M139.20M
FY198831 Dec 1988-1.76%-1.20M68.00M
FY198731 Dec 1987-33.28%-22.60M67.90M
FY198631 Dec 1986-31.58%-28.20M89.30M
FY198531 Dec 1985-25.50%-19.10M74.90M

Figures in USD. A quarter's revenue, net income and dividends are those of its last four quarters.

See also:P/E ratio,Market cap,P/S ratio,Debt to equity,Current ratio,All ratios

Common questions about Biogen's ROE

Source: Financial Modeling Prep